Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale

Eric J. Chow, Mark W. Tenforde, Melissa A. Rolfes, Benjamin Lee, Shreya Chodisetty, Julio A. Ramirez, Alicia M. Fry, Manish M. Patel

1 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. 2 Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. 3 Division of Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, United States of America

* mpatel@cdc.gov

Abstract

Background

Experimental studies have shown that vaccination can reduce viral replication to attenuate progression of influenza-associated lower respiratory tract illness (LRTI). However, clinical studies are conflicting, possibly due to use of non-specific outcomes reflecting a mix of large and small airway LRTI lacking specificity for acute lung or organ injury.

Methods

We developed a global ordinal scale to differentiate large and small airway LRTI in hospitalized adults with influenza using physiologic features and interventions (PFIs): vital signs, laboratory and radiographic findings, and clinical interventions. We reviewed the literature to identify common PFIs across 9 existing scales of pneumonia and sepsis severity. We characterized patients using this scale, we applied the scale to an antiviral clinical trial dataset where these PFIs were measured through routine clinical care in adults hospitalized with influenza-associated LRTI during the 2010–2013 seasons.

Results

We evaluated 12 clinical parameters among 1020 adults; 210 (21%) had laboratory-confirmed influenza, with a median severity score of 4.5 (interquartile range, 2–8). Among influenza cases, median age was 63 years, 20% were hospitalized in the prior 90 days, 50% had chronic obstructive pulmonary disease, and 22% had congestive heart failure. Primary influencers of higher score included pulmonary infiltrates on imaging (48.1%), heart rate >110 beats/minute (41.4%), oxygen saturation <93% (47.6%) and respiratory rate >24 breaths/
minute (21.0%). Key PFIs distinguishing patients with severity < or ≥8 (upper quartile) included infiltrates (27.1% vs 90.0%), temperature ≥ 39.1°C or < 36.0°C (7.1% vs 27.1%), respiratory rate > 24 breaths/minute (7.9% vs 47.1%), heart rate ≥ 110 beats/minute (29.3% vs 65.7%), oxygen saturation < 90% (14.3% vs 31.4%), white blood cell count > 15,000 (5.0% vs 27.2%), and need for invasive or non-invasive mechanical ventilation (2.1% vs 15.7%).

Conclusion
We developed a scale in adults hospitalized with influenza-associated LRTI demonstrating a broad distribution of physiologic severity which may be useful for future studies evaluating the disease attenuating effects of influenza vaccination or other therapeutics.

Introduction
Influenza virus infection can range in clinical severity from asymptomatic to severe symptomatic illness that might be fatal [1–6]. Vaccination confers partial protection against medically attended illness from any influenza virus infection, estimated from 22%-64%, and varies from year to year [7]. As breakthrough infections may occur after vaccination, it is important to also understand if vaccination reduces the severity of illness (i.e., attenuates disease) which may help promote the public health benefits of annual vaccination [8–10]. For childhood vaccines that provide partial protection in a population, protection might be higher against severe disease as compared with milder illness, which could influence vaccination policies and decisions [11–15]. For example, on the promise of attenuating disease severity, second-generation rotavirus vaccines have been successfully deployed worldwide resulting in marked reductions in rotavirus deaths and hospitalizations [12, 16, 17].

Characterization of disease attenuating effects of vaccination in real-world conditions requires two important considerations. First, a standardized definition of acute illness severity is necessary. Second, this severity definition must be specific for the acute pathology that immunity is expected to attenuate. The pathology of influenza-associated lower respiratory tract infection (LRTI) can be varied and include immunopathology from pro-inflammatory immune responses, direct virus-mediated damage, or inflammation related to bacterial superinfection [3, 18–21]. Triggers for the immunopathology include tropism of the influenza virus (seasonal, pandemic vs novel influenza viruses), virus dose, site of inoculum (upper vs lower airway), and host defense mechanisms or genetic susceptibility [3, 22–29]. Disease may be confined to the large airway, causing transient tracheobronchitis (herein referred to as non-severe LRTI) [3, 6]. However, viral damage may also extend to small airways, causing acute lung injury, primary viral pneumonia, or secondary bacterial infection, with or without systemic extrapulmonary involvement (herein referred as severe LRTI) [4, 5, 18]. In the absence of pre-existing mucosal immunity, breakthrough infections can occur but recall of immune responses after infection might attenuate influenza disease by limiting viral replication and spread to the small airway or extrapulmonary organ systems [27, 30–41].

While experimental virus challenge studies in animals and humans have shown the attenuating effects of influenza vaccination [27, 30–41], evidence from clinical studies is conflicting [10, 42–44]. The discrepancy might be due to clinical studies relying on non-specific outcomes such as influenza-associated hospitalization or intensive care unit admission (ICU) as surrogates for disease progression that vaccination is expected to attenuate. However, clinical
outcomes are influenced not only by severity of LRTI but also by factors such as age, underlying conditions, and healthcare seeking and treatment practices. For example, while influenza tracheobronchitis in healthy hosts often results in an uncomplicated clinical course, infection in patients with compromised reserve (e.g., chronic obstructive pulmonary disease [COPD] or frailty) can trigger complicated outcomes such as hospitalization, ICU admission, or death [44]. In turn, patients hospitalized with LRTI can be a mix of complicated large airway LRTI and small airway LRTI. To the extent that immunity confines infection to the large airways, clinically differentiating disease pathology is important for evaluating vaccine-mediated disease attenuation. Quantifying severity using a “global” ordinal scale inclusive of clinical features, clinical interventions, laboratory values, and imaging findings that correlate with pathology can improve the specificity of disease outcomes that vaccination can attenuate and reproducibility of studies evaluating influenza vaccine effectiveness against severe disease [13, 14]. Such a global scale grades disease severity based on pre-specified parameters assumed to be associated with acute infection and cannot be validated like traditional severity scores designed to “predict” poor clinical outcomes. The U.S. Food and Drug Administration recognizes that in absence of a single, gold standard endpoint for seriously ill hospitalized influenza patients, clinical trials should consider clinical severity endpoints on an ordinal scale [45]. An expert Working Group on influenza therapeutic trials proposed the development of such an ordinal scale for facilitating the evaluation of efficacy of antivirals among hospitalized patients and the World Health Organization adopted a similar approach for evaluating COVID-19 vaccines [46, 47]. To our knowledge, such an ordinal scale does not exist for evaluation of influenza vaccine-mediated disease attenuation.

Our hypothesis is that illness severity relates to viral inoculum and replication, and that viral spread results in hyperinflammation and severe LRTI [2, 4–6, 22, 23, 27, 33, 48]. Our study aims were: 1) to identify quantitative clinical features that might differentiate non-severe and severe LRTI among hospitalized patients; 2) to develop a scale to grade influenza illness using these clinical features; and 3) to apply and evaluate the scale to categorize and compare the severity of influenza in patients in a clinical trial dataset.

Methods

Physiological parameters and clinical interventions correlating with critical illness

As compared with non-severe LRTI requiring hospitalization, we hypothesized that patients with severe LRTI would be more likely to manifest derangements in physiological parameters from normal values and require intensive clinical interventions. We took a systematic approach to identify quantitative physiological features and interventions (PFI) associated with severity of acute respiratory illness or sepsis. We focused on a parsimonious set of PFIs that 1) were consistently identified across various contemporary severity scores; 2) were practical to collect among hospitalized patients; and 3) allowed grading of a spectrum of LRTI [3].

We first performed a qualitative search of the literature to identify commonly used contemporary severity scores associated with critical outcomes in patients with influenza and non-influenza acute respiratory illness and sepsis. We searched PubMed MEDLINE between January 2000 – December 2020 for “influenza” OR “community-acquired pneumonia” OR “sepsis” AND “severity” AND “scale” OR “score” OR “model” OR “prediction.” We excluded severity scores related to COVID-19 due to absence of co-circulation with influenza and the unique presentation of severe COVID-19 compared with influenza [49]. We included all-cause pneumonia and sepsis because severity scores confined to laboratory-confirmed influenza are scarce and because of the likely overlaps in the physiological features of clinical deterioration.
in these conditions [50–52]. We also surmised that physiological features for these conditions would capture acute extrapulmonary manifestations of influenza virus infection such as cardiac injury, encephalopathy, and other organ dysfunctions [4].

From a review of abstracts, we identified contemporary studies that developed and validated scores or identified physiological parameters predicting critical illness. We reviewed the reference lists of all included articles and reviews to identify key additional sources of data, particularly older versions of updated severity scores. From this search, we identified nine severity scores or studies that defined physiological parameters associated with critical illness (Table 1) [53–61].

**Developing the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale**

To overcome the challenges of using outcome-based scales that were not designed to evaluate vaccination-mediated attenuation, we creatively developed the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale based on PFIs. First, two clinicians (EC and MP) reviewed severity scores and predictors of illness severity and used clinical judgment to discern physiological features of acute illness severity that were common across the scores and studies, emphasizing parameters that are typically available in hospitalized patients (Table 1). We categorized PFIs into four groups: vital signs (temperature, respiratory rate, heart rate, mean arterial pressure, pulse oximetric or oxygen saturation); laboratory findings (white blood cell count, serum sodium, arterial blood gas pH); clinical findings (pulmonary infiltrate on imaging; acute mental status changes); and clinical interventions (vasopressor use and mechanical ventilation) (Table 2). Discrepancies in characterization were adjudicated through consensus.

Second, we developed the modifiable IDEAS scale by allocating points to each of the PFI. Values of PFIs were considered during the first 24 hours of admission, except for vasopressor use, or mechanical ventilation. Use of SpO2/FIO2 (where SpO2 represents the oxygen saturation and FIO2 represents fractional inspired oxygen ratio) would be favorable to oxygen saturation alone [62], although FIO2 concentrations might not be recorded in all datasets. We modeled our approach after “track-and-trigger” systems that have been used in various settings globally to use physiological parameters to identify and treat patients with clinical deterioration [50–52, 63]. The magnitude of the scoring reflects the deviation of the parameter from the norm. The individual scores of each PFI would be aggregated to develop a global score for each patient. With the exception of infiltrate on imaging, each PFI was based on a 0–3 point scale (either continuous or dichotomous), using cutoffs established by scores from which the PFI was derived. We weighted three of the PFIs based on our understanding of influenza pathogenesis that considers evidence from experimental inoculation studies and clinical experience. We up-weighted presence of infiltrates on imaging to a score of 5 to account for lower lung injury, which we deem to be a primary manifestation of severe influenza illness that vaccination is expected to attenuate. We down-weighted two common features of hospitalized patients that might bias the score upward and promote misclassification of disease severity: 1) Age [64]: we subtracted 2 points from the global score for age >70 years to account for higher prevalence of baseline derangements that overlap with acute illness severity (e.g., dementia or baseline abnormalities in sodium levels) and poor physiologic reserve that increases mortality which could lower the threshold for requiring interventions such as ventilation. 2) Underlying conditions [65, 66]: we subtracted points from PFI features that could be affected by presence of congestive heart failure (oxygen saturation, ventilation, serum sodium levels, or respiratory rate) and chronic lung disease (oxygen saturation, ventilation, or respiratory rate) commonly seen in adult patients hospitalized with acute respiratory illness.
Table 1. Published severity scores* informing the physiologic features and interventions for the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale.

| Variable Name             | Severity Index or Study          |
|--------------------------|----------------------------------|
| Temperature              | APACHE II                        |
|                         | National Early Warning Score     |
|                         | Pneumonia Severity Index         |
|                         | Simple Clinical Score            |
|                         | Simplified Acute Physiology Score II |
| Respiratory Rate         | APACHE II                        |
|                         | CURB-65                           |
|                         | National Early Warning Score     |
|                         | Pneumonia Severity Index         |
|                         | SMART-COP                         |
|                         | qSOFA                             |
|                         | Simple Clinical Score             |
| Heart Rate               | APACHE II                        |
|                         | National Early Warning Score     |
|                         | Pneumonia Severity Index         |
|                         | SMART-COP                         |
|                         | Simple Clinical Score             |
|                         | Simplified Acute Physiology Score II |
| Mean Arterial Pressure   | APACHE II                        |
|                         | SOFA                              |
| Oxygen Saturation        | National Early Warning Score     |
|                         | SOFA*                             |
|                         | SMART-COP                         |
|                         | Simple Clinical Score             |
| White Blood Cell Count   | APACHE II                        |
|                         | Simplified Acute Physiology Score II |
| Serum Sodium             | APACHE II                        |
|                         | Pneumonia Severity Index         |
|                         | Simplified Acute Physiology Score II |
| Arterial Blood Gas, pH   | APACHE II                        |
|                         | Pneumonia Severity Index         |
|                         | SMART-COP                         |
| Altered Mental Status    | National Early Warning Score     |
|                         | Pneumonia Severity Index         |
|                         | qSOFA                             |
|                         | Simple Clinical Score             |
|                         | CURB-65                           |
| Infiltrate on Imaging    | SMART-COP                         |
| Vasopressor Use          | SOFA                              |
| Mechanical Ventilation   | SOFA                              |

Abbreviations: APACHE II = Acute Physiologic Assessment and Chronic Health Evaluation II; CURB-65 = Confusion, Urea > 7 mmol/l, Respiratory rate ≥ 30/min, and low Blood pressure (diastolic blood pressure ≤ 60 mm Hg or systolic blood pressure < 90 mm Hg, age ≥ 65 years; SMART-COP = Systolic blood pressure, Multilobar chest radiography involvement, Albumin level, Respiratory rate, Tachycardia, Confusion, Oxygenation, and arterial pH; qSOFA = Quick Sequential Organ Failure Assessment; SOFA = Sequential Organ Failure Assessment.  
* References in the primary manuscript: APACHE II [56], National Early Warning Score [53], Pneumonia Severity Index [55], Simplified Clinical Score [60], Simplified Acute Physiology Score II [57], CURB-65 [58], SMART-COP [61], qSOFA [59], SOFA [54].  
* Note that the SOFA score uses partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) ratio.
Table 2. Point Allocation based on Physiologic Features and Interventions (PFI) for the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale.

| Category           | Severity Variables          | Value Ranges            | Point Allocation | Subtracting Points |
|--------------------|------------------------------|-------------------------|------------------|--------------------|
| Vital Signs        | Temperature                  | ≥ 39.1                  | 3                | -2 from the total score for age > 70 |
|                    |                              | 38.1–39.0               | 2                |                    |
|                    |                              | 36.1–38.0               | 0                |                    |
|                    |                              | 35.1–36.0               | 2                |                    |
|                    |                              | < 35.1                  | 3                |                    |
|                    | Respiratory Rate, breaths/min| ≥25                     | 3                |                    |
|                    |                              | <25                     | 0                |                    |
|                    | Heart Rate, beats/min        | >130                    | 3                | -1 if patient has history of CLD* or CHF |
|                    |                              | 110–130                 | 2                |                    |
|                    |                              | 60–109                  | 0                |                    |
|                    |                              | 41–59                   | 1                |                    |
|                    |                              | <40                     | 3                |                    |
|                    | Mean Arterial Pressure, mmHg | < 60                    | 3                |                    |
|                    |                              | ≥60                     | 0                |                    |
|                    | Oxygen Saturation, %         | > 93%                   | 0                |                    |
|                    |                              | 90–93%                  | 2                |                    |
|                    |                              | <90%                    | 3                |                    |
| Laboratory Findings| White Blood Cell Count, cells x10³/mm³ | ≥40                     | 3                |                    |
|                    |                              | 20–39                   | 2                |                    |
|                    |                              | 15–19                   | 1                |                    |
|                    |                              | 3–14                    | 0                |                    |
|                    |                              | 1–2                     | 1                |                    |
|                    |                              | <1                      | 2                |                    |
|                    | Serum Sodium, mEq/L,         | <120                    | 3                | -1 if patient has history of CHF |
|                    |                              | 120–125                 | 1                |                    |
|                    |                              | >125                    | 0                |                    |
|                    | Arterial Blood Gas, pH       | ≥7.6                    | 3                |                    |
|                    |                              | 7.5–7.59                | 1                |                    |
|                    |                              | 7.33–7.49               | 0                |                    |
|                    |                              | 7.25–7.32               | 1                |                    |
|                    |                              | <7.25                   | 3                |                    |
| Mental Status      | Altered Mental Status        | Altered                 | 2                |                    |
|                    | Not Altered                 | 0                       |                   |                    |
| In-Hospital Interventions | Infiltrate on Imaging | Yes                     | 5                |                    |
|                    |                              | No                      | 0                |                    |
|                    | Vasopressor Use              | Yes                     | 1                |                    |
|                    |                              | No                      | 0                |                    |
|                    | Mechanical Ventilation, days from symptom onset | Invasive 0–3 | 3 | -1 if patient has history of CLD or CHF |
|                    |                              | Invasive > 3            | 2                |                    |
|                    |                              | Noninvasive 0–3         | 2                |                    |
|                    |                              | Noninvasive >3          | 1                |                    |
|                    |                              | No mech vent            | 0                |                    |

Abbreviations: CHF = congestive heart failure; CLD = chronic lung disease.
* CLD is defined as history of chronic obstructive pulmonary disease or baseline home oxygen use.

https://doi.org/10.1371/journal.pone.0258482.t002
Applying the IDEAS scale

We applied the IDEAS scale to data from the Rapid Empiric Treatment with Oseltamivir Study (RETOS), a randomized clinical trial evaluating the effectiveness of oseltamivir treatment versus standard of care in adults (aged >18 years) hospitalized with LRTI in Louisville, Kentucky from 2010–2013 (clinicaltrials.gov, #NCT01248715) [67, 68]. In brief, patients were eligible for the study if they presented with clinician-diagnosed community-acquired pneumonia, acute exacerbation of COPD, or acute bronchitis and did not receive oseltamivir or zanamivir on hospital admission. All enrollees were systematically tested using a molecular assay (Luminex xTAG) for 12 respiratory viral pathogens by nasopharyngeal swab obtained by study staff. We included laboratory-confirmed influenza cases and patients who tested negative for influenza in the months between the first and last influenza case for each influenza season.

Data analysis

Because our primary motivation for developing IDEAS was to evaluate vaccine attenuation of influenza disease, we focused primarily on laboratory-confirmed influenza cases. Grading of disease severity in test-negative controls is not typically relevant for vaccine attenuation analysis. We conducted a descriptive analysis of the study cohort, using count (percentage) and median (interquartile range [IQR]) to summarize proportions and continuous variables. We assessed the distribution of the subjects on the severity scale using histograms and box plots. We stratified patients by the results of influenza testing. We used the upper quartile of the severity score to define high vs those in the bottom three quartiles as low severity and compared patient characteristics of these two groups. We looked at the frequency of PFIs in the patients with high and low severity scores and considered a 20% difference in prevalence to be a meaningful distinguishing feature. Mean difference in scores were also compared by patient characteristics. In the RETOS dataset, we did not impute for missingness and conducted a sensitivity analysis by removing variables from the IDEAS scale with more than 30% missingness in the dataset. Only pH by arterial blood gas met that criteria in the RETOS dataset with missing data on 56% of patients. Testing for statistical significance was conducted using the Pearson chi-squared tests to compare categorical variables or Wilcoxon rank-sum test for medians to compare continuous data. Statistical significance was established as p value <0.05. Data analysis was performed using SAS Version 9.4 (Cary, North Carolina). This activity was determined to meet the definition of research [45 CFR 46.102(l)] involving human subjects [45 CFR 46.102 (c)(1)] and Institutional Review Board (IRB) approval was provided by the University of Louisville Human Subjects Research Protection Program Office (Protocol 10.0465) and the Robley Rex Veterans Administration Medical Center IRB (protocol 0068/00325). The Centers for Disease Control and Prevention IRB granted reliance on local ethical review approvals. Written informed consent was obtained on all participants.

Results

Of the 1020 overall participants enrolled during the influenza seasons, 210 (20.5% had laboratory-confirmed influenza), the median age was 62 years (IQR, 52 to 72 years), 47.8% were female, 69.2% were overweight or obese, 80.6% were ever smokers (35.4% current smokers), and 28.2% were hospitalized in the prior 90 days before the index hospitalization. Underlying conditions were common: 70.4% had essential hypertension, 56.3% COPD, 37.3% diabetes mellitus, 29.1% coronary artery disease, and 26.6% had congestive heart failure.
Physiologic Features and Interventions (PFIs)

With the exception of presence of infiltrates on chest imaging, which was more common in patients without influenza, and white blood cell count, which was higher among patients without influenza, PFIs were generally similar between patients with and without influenza (Table 3). The severity score was non-normally distributed among patients with influenza (Fig 1), with a median score of 4.5 (IQR, 2 to 8; range, 0–20), including 70 (33%) with a score ≥8 and 140 (67%) with a score <8.

Among patients with influenza, the severity score was influenced by radiographic findings of pulmonary infiltrate (48.1%), heart rate ≥110 beats/minute (41.4%), oxygen saturations of 90–93% (27.6%) or <90% (20.0%), respiratory rate >24 breaths/minute (21.0%), temperature ≥39.1°C or <36.0°C (15.7%), invasive or non-invasive mechanical ventilation (6.7%), white blood cell count >20,000/mm³ (5.2%), altered mentation (4.8%), and mean arterial pressure <60 mmHg (4.3%) [Table 4].

Patients with high severity scores (≥8) were younger (median age 57.5 years, IQR: 45 to 69 years) than those with lower scores (median age 64.5, IQR: 55–77). PFIs that distinguished low vs high severity with difference in prevalence of ≥20% included: pulmonary infiltrates (27.1% vs 90.0%), respiratory rate >24 breaths/minute (7.9% vs 47.1%), temperature ≥39.1°C or <36.0°C (7.1% vs 27.1%), and heart rate >110 beats/minute (29.3% vs 65.7%), and white blood cell count >15,000 (5.0% vs 27.2%). In addition, as compared with patients with low severity, patients with high severity also were more likely to have oxygen saturations <90% (14.3% vs 31.4%) and to require invasive or non-invasive mechanical ventilation (2.1% vs 15.7%). Features that were uncommon or not different between high and low severity patients included serum sodium levels, altered mental status, vasopressor use, and arterial pH. No significant differences in underlying conditions were observed between those with severity score <8 or ≥8 (Table 5).

Discussion

Using a combination of severity scores to identify commonly available physiologic parameters of acute illness, we developed a quantitative scale that can grade illness severity of influenza-associated acute respiratory illness among hospitalized adults. Using a clinical trial dataset, we show that a gradient in severity exists among hospitalized patients with influenza and can be pragmatically quantified using vital signs, commonly available laboratory measurements, clinical findings, and critical interventions. In this cohort, highly prevalent findings that distinguished patients with higher scores from lower scores included pulmonary infiltrates, fever, and tachycardia; additional helpful features included respiratory rate and oxygen saturations. Such a scale could provide a standardized composite outcome for evaluating disease attenuating effects of influenza vaccination and improving reproducibility across studies. The IDEAS scale may have other applications as well, such as evaluating the clinical effectiveness of influenza antiviral therapies.

Studies evaluating the gradient of clinical severity of influenza virus infection in hospitalized patients from the perspective of immune-mediated disease attenuation or antiviral treatment are scarce. In experimental human virus challenge studies, pre-existing immunity or timely initiation of antiviral treatment can reduce symptom severity which correlates with viral replication and pro-inflammatory cytokine levels [2, 30–32, 35, 36, 38, 69, 70]. An absence of pre-existing immunity (e.g., through lack of vaccination) may result in progression of disease pathology from the upper respiratory tract to the lungs. Thus, measuring disease attenuating effects of vaccination or antiviral treatments would necessitate a standardized scale that differentiates acute disease limited to the upper airway from disease that has spread to the
Table 3. Comparison of Physiologic Features and Interventions (PFI) in hospitalized adults with lower respiratory tract infection, by influenza status.

|                                      | Influenza + | Influenza - | P-value |
|--------------------------------------|-------------|-------------|---------|
|                                      | n = 210     | n = 810     |         |
| **Demographics**                     |             |             |         |
| Age, years, Median (IQR)             | 63 (52–75)  | 62 (52–72)  | 0.34    |
| Female                               | 121 57.6    | 367 45.3    | <0.01   |
| **Vital Signs**                      |             |             |         |
| Temperature, °C, Median (IQR)        | 37.4 (36.8–38.2) | 37.0 (36.7–37.6) | <0.01 |
| <35.1                                | 0 0         | 1 0.1       | <0.01   |
| 35.1–36.0                            | 4 1.9       | 22 2.7      |         |
| 36.1–38.0                            | 145 69.1    | 666 82.2    |         |
| 38.1–39.0                            | 32 15.2     | 92 11.4     |         |
| ≥39.1                                | 29 13.8     | 29 3.6      |         |
| **Respiratory Rate, Breaths/Minute, Median (IQR)** | 21 (20–24) | 20 (18–24) | 0.26    |
| <9                                   | 0 0         | 0 0         | 0.43    |
| 9–11                                 | 0 0         | 0 0         |         |
| 12–20                                | 103 49.1    | 438 54.1    |         |
| 21–24                                | 63 30.0     | 218 26.9    |         |
| >24                                  | 44 21.0     | 154 19.0    |         |
| **Heart Rate, Beats/Minute, Median (IQR)** | 104 (91–116) | 99 (87–112) | <0.01   |
| ≤40                                  | 0 0         | 0 0         | 0.05    |
| 41–59                                | 5 2.4       | 26 3.2      |         |
| 60–109                               | 118 56.2    | 530 65.4    |         |
| 110–130                              | 69 32.9     | 201 24.8    |         |
| >130                                 | 18 8.6      | 53 6.5      |         |
| **Mean Arterial Pressure, mmHg, Median (IQR)** | 91 (79–106) | 94 (82–107) | 0.03    |
| <60                                  | 9 4.3       | 18 2.2      | 0.1     |
| ≥60                                  | 201 95.7    | 792 97.8    |         |
| **Oxygen Saturation, %**             | 94 (90–97)  | 94 (90–96)  | 0.86    |
| <90%                                 | 42 20       | 152 18.8    | 0.85    |
| 90–93%                               | 58 27.6     | 238 29.4    |         |
| >93%                                 | 110 52.4    | 420 51.8    |         |
| **Laboratory Values**                |             |             |         |
| WBC Count, x10^9 Cells/L, Median (IQR) [missing = 1] | 8.9 (6.2–12.0) | 11.9 (8.6–16.1) | <0.01 |
| <1                                   | 0 0         | 1 0.1       | <0.01   |
| 1–2                                  | 10 4.8      | 6 0.7       |         |
| 3–14                                 | 174 82.9    | 551 68.1    |         |
| 15–19                                | 15 7.1      | 155 19.2    |         |
| 20–39                                | 11 5.2      | 92 11.4     |         |
| ≥40                                  | 0 0         | 4 0.5       |         |
| Sodium, mEq/L, Median (IQR)          | 137 (134–139)| 138 (135–140)| 0.05   |
| <120                                 | 0 0         | 2 0.3       | 0.49    |
| 120–125                              | 1 0.5       | 10 1.2      |         |
| ≥125                                 | 209 99.5    | 798 98.5    |         |
| Arterial Blood Gas, pH, Median (IQR) [missing = 550] | 7.40 (7.36–7.44) | 7.41 (7.38–7.45) | 0.15   |

(Continued)
lower airway or systemically. However, published scales of disease severity do not differentiate these acute disease processes of influenza virus infection and are designed to predict outcomes such as length of stay, ICU admission, or mortality [54–58, 60, 61]. When evaluating

|                      | Influenza + | Influenza - |
|----------------------|-------------|-------------|
|                      | n = 210     | n = 810     |
| <7.25                | 4           | 11          |
| 7.25–7.32            | 6           | 34          |
| 7.33–7.49            | 73          | 312         |
| 7.5–7.59             | 3           | 25          |
| ≥7.6                 | 0           | 2           |

Abbreviations: CT = computed tomography; IQR = interquartile range; WBC = white blood cell.

1 “Global” scale inclusive of clinical features, clinical interventions, laboratory values, and imaging findings.

https://doi.org/10.1371/journal.pone.0258482.t003

Fig 1. Distribution of hospitalized influenza-positive patients based on the maximum score on the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale.

https://doi.org/10.1371/journal.pone.0258482.g001
### Table 4. Physiologic features and interventions among hospitalized influenza-positive patients by severity score.

| Patients with Laboratory Confirmed Influenza | Severity Score < 8 | Severity Score ≥ 8 |
|---------------------------------------------|--------------------|--------------------|
|                                             | n = 140            | n = 70              |
|                                             | n %                | n %                |
| **Demographics**                            |                    |                    |
| Age, years, Median (IQR)                    | 64.5 (55–77)       | 57.5 (45–69)       |
| Female                                      | 78                  | 43                  |
|                                             | 55.7                | 61.4                |
|                                             | 0.43                | 0.43                |
| **Vital Signs**                             |                    |                    |
| Temperature, °C, Median (IQR)               | 37.3 (36.8–37.9)   | 37.9 (37.1–39.1)   |
| < 35.1                                      | 0                  | 0                  |
| 35.1–36.0                                   | 1                  | 0.7                |
| 36.1–38.0                                   | 112                | 80.0               |
| 38.1–39.0                                   | 17                 | 12.1               |
| > 39.1                                      | 10                 | 7.1                |
| Respiratory Rate, Breaths/Minute, Median (IQR) | 20 (18–22) | 24 (20–28)        |
| < 9                                         | 0                  | 0                  |
| 9–11                                        | 0                  | 0                  |
| 12–20                                       | 84                 | 60.0               |
| 21–24                                       | 45                 | 32.1               |
| > 24                                        | 11                 | 7.9                |
| Heart Rate, Beats/Minute, Median (IQR)      | 99 (88–113)        | 114.5 (101–126)    |
| < 40                                        | 0                  | 0                  |
| 41–59                                       | 4                  | 2.9                |
| 60–109                                      | 95                 | 67.9               |
| 110–130                                     | 34                 | 24.3               |
| >130                                        | 7                  | 5.0                |
| Mean Arterial Pressure, mmHg, Median (IQR)  | 91 (80–103)        | 92 (77–109)        |
| < 60                                        | 2                  | 1.4                |
| ≥60                                         | 138                | 98.6               |
| Oxygen Saturation, %, Median (IQR)          | 94 (91–97)         | 92 (88–95)         |
| < 90%                                       | 20                 | 14.3               |
| 90–93%                                      | 40                 | 28.6               |
| > 93%                                       | 80                 | 57.1               |
| **Laboratory Values**                       |                    |                    |
| WBC Count, x10⁹ Cells/L, Median (IQR)       | 7.7 (5.7–10.6)     | 11.2 (7.3–15.2)    |
| < 1                                         | 0                  | 0                  |
| 1–2                                         | 7                  | 5.0                |
| 3–14                                        | 126                | 90.0               |
| 15–19                                       | 5                  | 3.6                |
| 20–39                                       | 2                  | 1.4                |
| ≥40                                         | 0                  | 0                  |
| Serum Sodium, mEq/L, Median (IQR)           | 137 (134–140)      | 136 (134–139)      |
| <120                                        | 0                  | 0                  |
| 120–125                                     | 0                  | 1                  |
| ≥125                                        | 140                | 99.6               |
| ABG, pH, Median (IQR) [missing = 124]       | 7.41 (7.36–7.44)   | 7.40 (7.36–7.44)   |

(Continued)
attenuating effects of vaccination or antiviral treatments, use of such non-specific outcomes can lead to biases from other factors including physiologic reserve, healthcare seeking patterns, and admission practices. Thus, we extracted predictors of severity that we deemed to be less influenced by these biases, focusing on parameters common across studies and those consistent with acute lung injury or systemic manifestations of infection. In our cohort, we identified the upper quartile to have the greatest derangement in PFIs. We suspect that this upper quartile of patients on the IDEAS scale is a better representation of patients with severe pathophysiology related to cytokine storm, acute respiratory distress syndrome, or extrapulmonary involvement after influenza virus infection. Ideally, attenuation would be measured capturing

Table 4. (Continued)

| Patients with Laboratory Confirmed Influenza | Severity Score < 8 | Severity Score ≥ 8 |
|--------------------------------------------|---------------------|---------------------|
|                                            | n = 140             | n = 70              |
|                                            | n   | %   | n   | %   | P-value |
| <7.25                                      | 0   | 0   | 4   | 9.1 | 0.07    |
| 7.25–7.32                                  | 5   | 11.9| 1   | 2.3 |         |
| 7.33–7.49                                  | 36  | 85.7| 37  | 84.1|         |
| 7.5–7.59                                   | 1   | 2.4 | 2   | 4.6 |         |
| ≥7.6                                       | 0   | 0   | 0   | 0   |         |

Outcomes and interventions

|                                | n = 140 | n = 70 | P-value |
|--------------------------------|---------|--------|---------|
| Altered Mental Status         | 6       | 4.3    | 4       | 5.7    | 0.65 |
| Infiltrate on Imaging (CXR or CT Scan) | 38     | 27.1   | 63     | 90.0   | <0.01 |
| Vasopressor Use               | 1       | 0.7    | 3       | 4.3    | 0.07 |
| Noninvasive or Invasive Ventilation | 3     | 2.1    | 11     | 15.7   | <0.01 |

Abbreviations: ABG = Arterial Blood Gas; CT = computed tomography; CXR = Chest Radiograph; IQR = interquartile range; WBC = White Blood Cell.

https://doi.org/10.1371/journal.pone.0258482.t004

Table 5. Underlying conditions of hospitalized influenza-positive patients by severity score.

| Patients with Laboratory Confirmed Influenza | Severity Score | Severity score < 8 | Severity Score ≥ 8 |
|--------------------------------------------|---------------|--------------------|--------------------|
|                                            | n = 140       | n = 70             | P-value            |
|                                            | n   | %   | n   | %   |       |
| Active neoplasm                            | 13  | 9.3 | 9   | 12.9| 0.43 |
| Congestive heart failure                   | 32  | 22.9| 14  | 20.0| 0.64 |
| Coronary artery disease                    | 42  | 30.0| 17  | 24.3| 0.39 |
| Atrial fibrillation                        | 19  | 13.6| 11  | 15.7| 0.68 |
| Hypertension                               | 104 | 74.3| 46  | 65.7| 0.19 |
| Hyperlipidemia                             | 73  | 52.1| 31  | 44.3| 0.28 |
| Stroke                                     | 18  | 12.9| 8   | 11.4| 0.77 |
| Chronic renal disease                      | 28  | 20.0| 15  | 21.4| 0.81 |
| Liver disease                              | 8   | 5.7 | 4   | 5.7 | 1.0  |
| Diabetes mellitus                          | 51  | 36.4| 29  | 41.4| 0.48 |
| Chronic obstructive pulmonary disease       | 73  | 52.1| 31  | 44.3| 0.28 |
| Home oxygen use                            | 29  | 20.7| 8   | 11.4| 0.10 |
| Hospitalization in past 90 days            | 25  | 17.9| 16  | 22.9| 0.39 |

https://doi.org/10.1371/journal.pone.0258482.t005
the full spectrum of influenza from asymptomatic infection to severe illness. If vaccination attenuates disease among hospitalized patients, comparing vaccine effectiveness in the highest vs the lower quartile of the IDEAS scale could be a better representation of vaccination-mediated disease attenuation than using binary non-specific outcomes.

Typical features of lower respiratory tract involvement in previous influenza studies have included hypoxia and multi-lobar infiltrates, although fever, systemic manifestations of illness, and laboratory abnormalities are also common predictors of severity across studies [71–74]. We favored reduced missingness and improve practicality by focusing on factors that are routinely measured or easily accessible in clinical settings. For example, small single center studies have identified lactate and brain natriuretic peptide (BNP) as a predictor of poor outcomes in patients with community acquired pneumonia, but these were uncommonly measured markers in our dataset [75–77]. Interestingly, C-reactive protein has been a commonly measured marker and a reliable predictor of severity during the COVID-19 pandemic [78]. While, C-reactive protein levels have not been well-examined in patients with seasonal influenza, several small studies identified higher levels in patients with severe disease during the 2009 H1N1 pandemic [79]. Some studies during the 2009 H1N1 pandemic also identified predictors of influenza severity not included in our PFIs including IgM levels, age >45 years, sex, aspartate aminotransferase levels, or lactate dehydrogenase levels [72, 80, 81]. Use of PaO2/FiO2 or SpO2/FiO2 have also been favored over oxygen saturation alone in some studies, but FiO2 concentrations were not consistently recorded [62]. Scores grading the severity of pulmonary infiltrates on radiographs may be valuable rather than dichotomous interpretation, although this could require more specialized interpretation with potential issues of inter-rater reliability [73]. Our use of a broad range of PFIs likely has some collinearity with these variables that were not included in this study. Future refinement of these PFIs or adaptations to meet the needs of the database is encouraged. If a gradient is identified that reflects viral-mediated damage, the global severity scales should prove to be useful, reliable, and reproducible measure of evaluating the disease attenuating effects of vaccination or antiviral treatments.

We down-weighted pre-existing factors associated with derangements in PFIs unrelated to the acute infection that can misclassify patients as having severe LRTI. Here we considered age >70 years, COPD, and CHF to be such conditions because they are over-represented among patients hospitalized with LRTI and have baseline abnormalities that overlap with PFIs used to define severe influenza LRTI [44, 64, 66]. Other factors with similarly high prevalence may also warrant consideration when applying global IDEAS scale to other cohorts. For example, some cohorts may be derived from specialty hospitals with higher prevalence of immunocompromised patients. Trade-offs exist between parsimony and inclusiveness—not all pre-existing conditions or PFIs are practical choices to include in general severity score models. A falsely increased score due to a rare chronic condition or a lower score due to a missed PFI may misclassify disease severity for the individual patient, though this is less likely with an aggregate score using multiple PFIs, unless missingness is common across multiple PFIs. If misclassification occurs, it is most likely in patients with scores closer to the median value and thus approaches such as focusing on comparing effectiveness in the highest versus the lowest quartile could be used to evaluate disease attenuation.

Clinical studies evaluating disease attenuation associated with influenza vaccination have been scarce considering that vaccines were first developed over 80 years ago. Namely, most vaccine efficacy studies have focused on outcomes of any symptomatic influenza and not disease attenuation in vaccinated versus unvaccinated groups. A few clinical trials of inactivated and live-attenuated influenza vaccines in children have demonstrated higher efficacy against laboratory-confirmed influenza with severe endpoints (defined mostly by fever) compared with influenza of any severity [9, 82, 83]. Findings from observational studies in general have
been inconsistent possibly due to differences in outcomes, sample size, age differences, and influenza season. Some studies have suggested disease is attenuated in association with vaccination, through indirect measures of severity, including decreased ICU admission and reduced length of hospital stay [8, 10, 42, 84–86]. A few studies have also demonstrated higher point estimates of vaccine effectiveness against critical influenza illness versus non-critical illness, with setting of care being a correlate of disease severity [10, 85]. In one outpatient study, influenza vaccination was associated with reduced perceived symptom severity across eight systemic, upper respiratory, and lower respiratory symptoms among older adults but not in younger adults [87]. Other studies have not found differences in vaccine effectiveness between inpatient and outpatient settings [43, 44], or reduction in risk of severe disease among vaccinated cases [88–90]. Vaccination-associated reduction in disease severity in some observational studies has also varied by age and season [8, 42, 87]. The development and use of a standardized ordinal scale that uses objective indicators and endpoints of severity such as IDEAS could be valuable for evaluations of attenuation mediated by vaccination and antiviral treatment. Such scales have been successfully used for pertussis, varicella, and rotavirus disease to demonstrate vaccine effectiveness against progression of disease (termed VEp), conditioned on infection, as well as overall vaccine effectiveness of reducing susceptibility to a given outcome in the general population (termed VEs) [11, 13, 91]. Such analyses are key for evaluating whether partially protective vaccines can limit the severity of breakthrough infections in vaccinated persons as compared with infections in unvaccinated persons.

Our study should be interpreted in the context of some limitations. First, the IDEAS scale applied physiologic features and interventions that were based largely on studies evaluating all-cause pneumonia and sepsis, which are well-studied, and thus may be less specific to influenza that might also be affected by prior vaccination or infection history. Second, the selection of the PFIs was also informed by experimental inoculation studies in animals and humans and understanding of mechanisms of immunity as well as antiviral treatments [2, 30–32, 35, 36, 38, 69, 70]. Thus, the assumption that these features of influenza severity are relevant to measuring attenuating effects of vaccination or antiviral treatments cannot be empirically validated. Third, misclassification of patients into varying gradients of severity is possible if some of the included PFIs were affected for reasons unrelated to influenza virus replication or were missing non-randomly. However, the aggregated score based on multiple PFIs reduces misclassification related to derangements in individual PFIs. Fourth, the cut-offs for quantitative PFIs may not precisely correlate with severe disease in individual patients but have predicted severe outcomes in prior studies and were generally consistent across studies. Small alterations in cut-offs of the features are less likely to influence the severity grading when applying an aggregated score in a cohort of patients. Lastly, the generalizability of the score may vary but the score can be adapted or modified to identify a gradient of severity within a given dataset. The IDEAS scale was based on hospitalized patients alone and would not be relevant to outpatient settings but could be applied to grade severity in a large cohort that captures the breadth of outpatient and inpatient visits.

In summary, we reviewed outcomes-based sepsis, pneumonia, and influenza severity scores to identify objective physiologic features and interventions that differentiate a breadth of severity observed in patients hospitalized with influenza. Under the premise that vaccination and antiviral treatment reduces disease severity, reductions in the score based on these features would be expected in vaccinated patients or those receiving timely antiviral treatment. Further adaptation and implementation of the IDEAS scale under real-world settings might improve reproducibility and validity of trials and studies evaluating influenza disease attenuation after vaccination or antiviral treatment.
Supporting information

S1 Data.
(XLSX)

Acknowledgments

Disclaimers: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Author Contributions

Conceptualization: Eric J. Chow, Alicia M. Fry, Manish M. Patel.

Data curation: Eric J. Chow, Shreya Chodisetty.

Formal analysis: Eric J. Chow, Mark W. Tenforde, Benjamin Lee, Manish M. Patel.

Investigation: Eric J. Chow, Benjamin Lee, Shreya Chodisetty, Julio A. Ramirez.

Methodology: Eric J. Chow, Melissa A. Rolfes, Julio A. Ramirez, Manish M. Patel.

Supervision: Melissa A. Rolfes, Julio A. Ramirez, Alicia M. Fry, Manish M. Patel.

Validation: Mark W. Tenforde.

Writing – original draft: Manish M. Patel.

Writing – review & editing: Eric J. Chow, Mark W. Tenforde, Melissa A. Rolfes, Benjamin Lee, Shreya Chodisetty, Julio A. Ramirez, Alicia M. Fry.

References

1. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019; 23(1):214. Epub 2019/06/14. https://doi.org/10.1186/s13054-019-2491-9 PMID: 31189475; PubMed Central PMCID: PMC6563376.

2. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998; 101(3):643–9. Epub 1998/03/21. https://doi.org/10.1172/JCI1355 PMID: 9449698; PubMed Central PMCID: PMC508608.

3. Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr Opin Virol. 2012; 2(3):276–86. Epub 2012/06/20. https://doi.org/10.1016/j.coviro.2012.02.013 PMID: 22709515.

4. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017; 11(5):372–93. Epub 2017/07/27. https://doi.org/10.1111/irv.12470 PMID: 28745014; PubMed Central PMCID: PMC5596521.

5. Short KR, Kroeze E, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014; 14(1):57–69. Epub 2013/11/19. https://doi.org/10.1016/S1473-3099(13)70286-X PMID: 24239327.

6. Walsh JJ, Dietlein LF, Low FN, Burch GE, Mogabgab WJ. Bronchotracheal response in human influenza. Type A, Asian strain, as studied by light and electron microscopic examination of bronchoscopic biopsies. Arch Intern Med. 1961; 108:376–88. Epub 1961/09/01. https://doi.org/10.1001/archinte.1961.03620090048006 PMID: 13782910.

7. Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic. Vaccine. 2021; 39(8):1225–40. Epub 2021/01/27. https://doi.org/10.1016/j.vaccine.2021.01.032 PMID: 33494964.
8. Arriola CS, Anderson EJ, Baumbach J, Bennett N, Bohm S, Hill M, et al. Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012–2013 Season in the United States. J Infect Dis. 2015; 212(8):1200–8. Epub 2015/03/31. https://doi.org/10.1093/infdis/jiv200 PMID: 25821227; PubMed Central PMCID: PMC4683374.

9. Jain VK, Rivera L, Zaman K, Espós RA Jr., Sirivichayakul C, Quimambao BP, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013; 369(26):2481–91. Epub 2013/12/18. https://doi.org/10.1056/NEJMoa1315817 PMID: 24328444.

10. Thompson MG, Piresse N, Sue Huang Q, Prasad N, Duque J, Claire Newbern E, et al. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. Vaccine. 2018; 36(39):5916–25. Epub 2018/08/06. https://doi.org/10.1016/j.vaccine.2018.07.028 PMID: 30077480.

11. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009; 301(21):2243–51. Epub 2009/06/06. https://doi.org/10.1001/jama.2009.756 PMID: 19491186.

12. Patel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis. 2012; 12(7):561–70. Epub 2012/06/30. https://doi.org/10.1016/S1473-3099(12)70029-4 PMID: 22742639.

13. Preziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis. 2003; 37(6):772–9. Epub 2003/09/05. https://doi.org/10.1086/377270 PMID: 12955637.

14. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990; 22(3):259–67. Epub 1990/01/01. https://doi.org/10.3109/00365549009027046 PMID: 2371542.

15. Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis. 1990; 22(3):269–78. Epub 1990/01/01. https://doi.org/10.3109/00365549009027047 PMID: 2164706.

16. do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira WK, Cortez-Escalante JJ, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011; 8(4):e1001024. Epub 2011/04/29. https://doi.org/10.1371/journal.pmed.1001024 PMID: 21526226; PubMed Central PMCID: PMC3079643.

17. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med. 2011; 365(8):772–3. Epub 2011/08/26. https://doi.org/10.1056/NEJMoa1100062 PMID: 21864191.

18. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol. 2013; 191(5):2047–52. Epub 2013/06/22. https://doi.org/10.4049/jimmunol.1301152 PMID: 23964104; PubMed Central PMCID: PMC3760235.

19. Shieh WJ, Blau DM, Denison AM, Delemon-Carnes M, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathogenesis and implications for treatment. Eur Respir J. 2015; 45(5):1463–78. Epub 2015/03/21. https://doi.org/10.1183/09031936.00186214 PMID: 25792631.

20. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine. 2008; 26 Suppl 4:D59–66. Epub 2009/02/01. https://doi.org/10.1016/j.vaccine.2008.07.025 PMID: 19290162; PubMed Central PMCID: PMC2605683.

21. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med. 1966; 122(3):800–4. Epub 1966/07/01. https://doi.org/10.3181/00379727-122-31255 PMID: 5918954.

22. Little JW, Douglas RG Jr., Hall WJ, Roth FK. Attenuated influenza produced by experimental intranasal inoculation. J Med Virol. 1979; 3(3):177–88. Epub 1979/01/01. https://doi.org/10.1002/jmv.1890030303 PMID: 479857.

23. Shieh WJ, Blau DM, Denison AM, Delemon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010; 177(1):166–75. Epub 2010/05/29. https://doi.org/10.2353/ajpath.2010.100115 PMID: 20508031; PubMed Central PMCID: PMC2893660.

24. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature. 2006; 440(7083):435–6. Epub 2006/03/24. https://doi.org/10.1038/44035a PMID: 16554799.
26. Tellier R. Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface. 2009; 6 Suppl 6:S783–90. Epub 2009/09/24. https://doi.org/10.1098/rsif.2009.0302.focus PMID: 19773292; PubMed Central PMCID: PMC2843947.

27. Yetter RA, Lehrer S, Ramphal R, Small PA Jr., Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun. 1980; 29(2):654–62. Epub 1980/08/01. https://doi.org/10.1128/iai.29.2.654-662.1980 PMID: 721633; PubMed Central PMCID: PMC551177.

28. Gounder AP, Boon ACM. Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease. J Immunol. 2019; 202(2):341–50. Epub 2019/01/09. https://doi.org/10.4049/jimmunol.1801010 PMID: 30617115; PubMed Central PMCID: PMC6327976.

29. Patel MM, York I, Monto A, Thompson MG, Fry AM. Attenuation of post-infection influenza illness—opportunities and challenges. Lancet Microbe. 2021. in press, 3 August 2021.

30. Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. MBio. 2016; 7(2):e00417–16. Epub 2016/04/21. https://doi.org/10.1128/mBio.00417-16 PMID: 27094330; PubMed Central PMCID: PMC4959521.

31. Henle W, Henle G, et al. Experimental exposure of human subjects to viruses of influenza. J Immunol. 1946; 52:145–65. Epub 1946/02/01. PMID: 21018818.

32. Morris JA, Kasel JA, Saglam M, Knight V, Loda FA. Immunity to influenza as related to antibody levels. N Engl J Med. 1966; 274(10):527–35. Epub 1966/03/10. https://doi.org/10.1056/NEJM196603102741001 PMID: 5907488.

33. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis. 1974; 129(4):411–20. Epub 1974/04/01. https://doi.org/10.1093/infdis/129.4.411 PMID: 4593871.

34. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol. 1983; 37:529–49. Epub 1983/01/01. https://doi.org/10.1146/annurev.mi.37.100183.002525 PMID: 6357060.

35. Francis T, Pearson HE, Salk JE, Brown PN. Immunity in Human Subjects Artificially Infected with Influenza Virus, Type B. Am J Public Health Nations Health. 1944; 34(4):317–34. Epub 1944/04/01. https://doi.org/10.2105/ajph.34.4.317 PMID: 18015967; PubMed Central PMCID: PMC1625014.

36. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebnner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274–80. Epub 2012/01/31. https://doi.org/10.1038/nm.22286307.

37. Ramphal R, Cogliano RC, Shands JW Jr., Small PA Jr. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun. 1979; 25(3):992–7. Epub 1979/09/01. https://doi.org/10.1128/iai.25.3.992-997.1979 PMID: 500197; PubMed Central PMCID: PMC414546.

38. Bell JA, Ward TG, Kapikian AZ, Shelokov A, Reichelderfer TE, Huebner RJ. Artificially induced Asian influenza in vaccinated and unvaccinated volunteers. J Am Med Assoc. 1957; 165(11):1366–73. Epub 1957/11/16. https://doi.org/10.1001/jama.1957.02980290006002 PMID: 13475045.

39. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007; 4(2):e59. Epub 2007/02/15. https://doi.org/10.1371/journal.pmed.0040059 PMID: 17298168; PubMed Central PMCID: PMC1796909.

40. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine. 1993; 11(10):1037–9. Epub 1993/01/01. https://doi.org/10.1016/0264-410x(93)90130-p PMID: 8212824.

41. Schulman JL. Effects of immunity on transmission of influenza virus: experimental studies. Prog Med Virol. 1970; 12:128–60. Epub 1970/01/01. PMID: 4921481.

42. Arriola C, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM, et al. Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza. Clin Infect Dis. 2017; 65(8):1289–97. Epub 2017/05/20. https://doi.org/10.1093/cid/cix468 PMID: 28525597; PubMed Central PMCID: PMC5718038.

43. Feng S, Cowling BJ, Sullivan SG. Influenza vaccine effectiveness by test-negative design—Comparison of inpatient and outpatient settings. Vaccine. 2016; 34(14):1672–9. Epub 2016/02/28. https://doi.org/10.1016/j.vaccine.2016.02.039 PMID: 26920469; PubMed Central PMCID: PMC4826670.

44. Tenforde MW, Chung J, Smith ER, Talbot HK, Trabue CH, Zimmerman RK, et al. Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015–2018. Clin Infect Dis. 2020. Epub 2020/04/10. https://doi.org/10.1093/cid/ciaa407 PMID: 32270198.

45. (CDER) CdERa. Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/influenza.
developing-drugs-treatment-andor-prophylaxis. Last accessed 2 August 2021. U.S. Department of Health and Human Services, Food and Drug Administration; 2011.

46. Characterisation WHOWGotC, Management of C-1. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8):e192–e7. Epub 2020/06/17. https://doi.org/10.1016/S1473-3099(20)30483-7 PMID: 32539990; PubMed Central PMCID: PMC7292605.

47. King JC, Beigel JH, Ison MG, Rothman RE, Uyeki TM, Walker RE, et al. Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations. Open Forum Infect Dis. 2019; 6(4):ofz137. Epub 2019/05/01. https://doi.org/10.1093/ofid/ofz137 PMID: 31037242; PubMed Central PMCID: PMC6479095.

48. Sweet C, Bird RA, Howie AJ, Overton HA, Coates DM, Smith H. Further studies of the reasons for the lack of alveolar infection during influenza in ferrets. Br J Exp Pathol. 1985; 66(2):217–31. Epub 1985/04/01. PMID: 3885997; PubMed Central PMCID: PMC2041048.

49. Talbot HK, Martin ET, Gaglani M, Middleton DB, Ghamande S, Silveira FP, et al. Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators. Clin Infect Dis. 2021. Epub 2021/05/30. https://doi.org/10.1093/cid/ciab123 PMID: 34050639; PubMed Central PMCID: PMC8195096.

50. Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. VIEWS—Towards a national early warning score for detecting adult inpatient deterioration. Resuscitation. 2010; 81(8):932–7. Epub 2010/07/20. https://doi.org/10.1016/j.resuscitation.2010.04.014 PMID: 20637974.

51. Smith GB, Prytherch DR, Schmidt PE, Featherstone PI. Review and performance evaluation of aggregate weighted 'track and trigger' systems. Resuscitation. 2008; 77(2):170–9. Epub 2008/02/06. https://doi.org/10.1016/j.resuscitation.2007.12.004 PMID: 18249483.

52. Gao H, McDonnell A, Harrison DA, Moore T, Adam S, Daly K, et al. Systematic review and evaluation of physiological track and trigger warning systems for identifying at-risk patients on the ward. Intensive Care Med. 2007; 33(4):667–79. Epub 2007/02/24. https://doi.org/10.1007/s00134-007-0532-3 PMID: 17318499.

53. Royal College of Physicians. National Early Warning Score (NEWS)2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP, 2017. Available at: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2. Accessed 8 March 2021.

54. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001; 286(14):1754–8. Epub 2001/10/12. https://doi.org/10.1001/jama.286.14.1754 PMID: 11594901.

55. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243–50. Epub 1997/01/23. https://doi.org/10.1056/NEJM199701233360402 PMID: 8995086.

56. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818–29. Epub 1985/10/01. PMID: 3928249.

57. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270(24):2957–63. Epub 1993/12/22. https://doi.org/10.1001/jama.270.24.2957 PMID: 8254858.

58. Lim WS, van der Eerden MM, Laing RG, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377–82. Epub 2003/05/03. https://doi.org/10.1136/thorax.58.5.377 PMID: 12728155; PubMed Central PMCID: PMC1746657.

59. Seymour CW, Liu VX, Iwashyna TJ, Brunholtz FM, Rea TD, Scharag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):762–74. Epub 2016/02/24. https://doi.org/10.1001/jama.2016.0289 PMID: 26903335; PubMed Central PMCID: PMC5433435.

60. Subbe CP, Jishi F, Hibbs RA. The simple clinical score: a tool for benchmarking of emergency admissions in acute internal medicine. Clin Med (Lond). 2010; 10(4):352–7. Epub 2010/09/21. https://doi.org/10.7861/clinmedicine.10-4-352 PMID: 20849009; PubMed Central PMCID: PMC4952164.

61. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008; 47(3):375–84. Epub 2008/06/19. https://doi.org/10.1086/589754 PMID: 18558884.

62. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007; 132 (2):410–7. Epub 2007/06/19. https://doi.org/10.1378/chest.07-0617 PMID: 17573487.

63. Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive...
care unit admission, and death. Resuscitation. 2013; 84(4):465–70. Epub 2013/01/09. https://doi.org/10.1016/j.resuscitation.2012.12.016 PMID: 23295778.

64. Rosenthal GE, Kaboli PJ, Barnett MJ, Sirio CA. Age and the risk of in-hospital death: insights from a multihospital study of intensive care patients. J Am Geriatr Soc. 2002; 50(7):1205–12. Epub 2002/07/23. https://doi.org/10.1046/j.1532-5415.2002.50306.x PMID: 12133014.

65. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008; 52(5):347–56. Epub 2008/07/26. https://doi.org/10.1016/j.jacc.2008.04.028 PMID: 18652942.

66. O’Driscol BR, Grant K, Green D, Edeghere S, Bakerly ND, Murphy P, et al. The national early warning score gives misleading scores for oxygen saturation in patients at risk of hypercapnia. Clin Med (Lond). 2014; 14(6):695–6. Epub 2014/12/04. https://doi.org/10.7861/clinmedicine.14-6-695 PMID: 25468871; PubMed Central PMCID: PMC4954158.

67. Ramirez J, Peyrani P, Wierimenk T, Chaves SS, Fry AM. A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. Clin Infect Dis. 2018. Epub 2018/04/17. https://doi.org/10.1093/cid/ciy163 PMID: 29652942.

68. Chow EJ, Rolfes MA, Carrico RL, Furmanek S, Ramirez JA, Ferdinands JM, et al. Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010–2013. Open Forum Infect Dis. 2020; 7(7):ofaa262. Epub 2020/07/28. https://doi.org/10.1093/ofid/ofaa262 PMID: 32715020; PubMed Central PMCID: PMC7372707.

69. Jao RL, Wheelock EF, Jackson GG. Production of interferon in volunteers infected with Asian influenza. J Infect Dis. 1970; 121(4):419–26. Epub 1970/04/01. https://doi.org/10.1093/infdis/121.4.419 PMID: 5441118.

70. Oh WS, Lee SJ, Lee CS, Hur JA, Hur AC, Park YS, et al. A prediction rule to identify severe cases among adult patients hospitalized with pandemic influenza A (H1N1) 2009. J Korean Med Sci. 2011; 26(4):499–506. Epub 2011/04/07. https://doi.org/10.3346/jkms.2011.26.4.499 PMID: 21468256; PubMed Central PMCID: PMC3069568.

71. Capelastegui A, Quintana JM, Bilbao A, Esparza PP, Garin O, Alonso J, et al. Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission. Eur J Clin Microbiol Infect Dis. 2012; 31(10):2693–701. Epub 2012/04/25. https://doi.org/10.1007/s10096-012-1616-8 PMID: 22526871; PubMed Central PMCID: PMC7101595.

72. Nicolini A, Ferrera L, Rao F, Senarega R, Ferrari-Bravo M. Chest radiological findings of influenza A H1N1 pneumonia. Rev Port Pneumol. 2012; 18(3):120–7. Epub 2012/04/10. https://doi.org/10.1016/j.rppneu.2011.12.008 PMID: 22483844.

73. Adeniji KA, Cusack R. The Simple Triage Scoring System (STSS) successfully predicts mortality and critical care resource utilization in H1N1 pandemic flu: a retrospective analysis. Crit Care. 2011; 15(1):R39. Epub 2011/01/29. https://doi.org/10.1186/cc10001 PMID: 21269458; PubMed Central PMCID: PMC3221968.

74. Chen YX, Li CS. Lactate on emergency department arrival as a predictor of mortality and site-of-care in pneumonia patients: a cohort study. Thorax. 2015; 70(5):404–10. Epub 2015/02/27. https://doi.org/10.1136/thoraxjnl-2014-206461 PMID: 25716454.

75. Ning P, Zheng Y, Luo Q, Liu X, Kang Y, Zhang Y, et al. Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity. Crit Care. 2018; 22(1):130. Epub 2018/05/16. https://doi.org/10.1186/s13054-018-2049-2 PMID: 29759075; PubMed Central PMCID: PMC5952829.

76. Zhou H, Lan T, Guo S. Stratified and prognostic value of admission lactate and severity scores in patients with community-acquired pneumonia in emergency department: A single-center retrospective cohort study. Medicine (Baltimore). 2019; 88(41):e17479. Epub 2019/10/09. https://doi.org/10.1097/MD.00000000000017479 PMID: 31593111; PubMed Central PMCID: PMC6799603.

77. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020; 92(11):2409–11. Epub 2020/06/10. https://doi.org/10.1002/jmv.26097 PMID: 32516845; PubMed Central PMCID: PMC7301027.

78. Vasiljeva D, Badawi A. C-reactive protein as a biomarker of severe H1N1 influenza. Inflamm Res. 2019; 68(1):39–46. Epub 2018/10/06. https://doi.org/10.1007/s00011-018-1188-x PMID: 30288556; PubMed Central PMCID: PMC6314979.
80. Justel M, Socías L, Almansa R, Ramírez P, Gallegos MC, Fernández V, et al. IgM levels in plasma predict outcome in severe pandemic influenza. J Clin Virol. 2013; 58(3):564–7. Epub 2013/10/01. https://doi.org/10.1016/j.jcv.2013.09.006 PMID: 24076102.

81. Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J. 2014; 8(2):185–91. Epub 2013/10/11. https://doi.org/10.1111/crj.12056 PMID: 24106842; PubMed Central PMCID: PMC4204512.

82. Ambrose CS, Wu X, Caspard H, Belshe RB. Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. Vaccine. 2014; 32(43):5546–8. Epub 2014/08/19. https://doi.org/10.1016/j.vaccine.2014.07.097 PMID: 25131746.

83. Danier J, Rivera L, Claey s C, Dbaibo G, Jain VK, Kosalaraksa P, et al. Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine. Pediatr Infect Dis J. 2019; 38(8):866–72. Epub 2019/07/16. https://doi.org/10.1097/INF.0000000000002387 PMID: 31306399.

84. Casado I, Dominguez A, Toledo D, Chamorro J, Force L, Soldevila N, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Rev Vaccines. 2016; 15(3):425–32. Epub 2015/12/23. https://doi.org/10.1586/14760584.2016.1134328 PMID: 26690376.

85. Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis. 2013; 57(2):167–75. Epub 2013/03/28. https://doi.org/10.1093/cid/cit194 PMID: 23532475.

86. Catania J, Que LG, Govert JA, Hollingsworth JW, Wolfe CR. High intensive care unit admission rate for 2013–2014 influenza is associated with a low rate of vaccination. Am J Respir Crit Care Med. 2014; 189(4):485–7. Epub 2014/02/12. https://doi.org/10.1164/rccm.201401-0066LE PMID: 24512430; PubMed Central PMCID: PMC3977724.

87. VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis. 2014; 14:231. Epub 2014/06/03. https://doi.org/10.1186/1471-2334-14-231 PMID: 24894932; PubMed Central PMCID: PMC4013802.

88. Blyth CC, Macartney KK, McRae J, Clark JE, Marshall HS, Bretty J, et al. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. Clin Infect Dis. 2019; 68(6):940–8. Epub 2018/08/24. https://doi.org/10.1093/cid/ciy597 PMID: 30137244.

89. Joshi M, Chandra D, Mittadodia P, Bartter T. The impact of vaccination on influenza-related respiratory failure and mortality in hospitalized elderly patients over the 2013–2014 season. Open Respir Med J. 2015; 9:9–14. Epub 2015/03/13. https://doi.org/10.2174/1874306401509010009 PMID: 25763116; PubMed Central PMCID: PMC4348731.

90. Segaloff HE, Petrie JG, Malosh RE, Cheng CK, McSpadden EJ, Ferdinands JM, et al. Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014–2015 and 2015–2016. Epidemiol Infect. 2018; 146(11):1350–8. Epub 2018/06/09. https://doi.org/10.1017/S0950268818001486 PMID: 29880077; PubMed Central PMCID: PMC6089216.

91. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001; 344(13):955–60. Epub 2001/03/29. https://doi.org/10.1056/NEJM200103293441302 PMID: 11274621.